RA Capital Management, an American investment firm, led a $240m investment in Cidara Therapeutics, a biotechnology company, with participation from Bain Capital Life Sciences, BVF Partners and Canaan Partners. “We have followed the development of CD388 over time with great interest. As stage-agnostic company builders, we were excited to catalyze this reacquisition and financing – and to leverage the company-building capabilities of our RAVen incubator to support Cidara,” Laura Tadvalkar, RA Capital Management Managing Director.